News

The 2024 edition of the Union World Conference on Lung Health offered an excellent opportunity for the TB-CAPT consortium to present results from its research activities implemented during the five years of the project’s lifetime.

The TB-CAPT XDR trial has demonstrated the efficacy of the WHO-approved Xpert MTB/XDR test in detecting Mycobacterium tuberculosis and resistance to crucial drugs directly from sputum specimens.

Members from the TB-CAPT, PanACEA, Seq&Treat and PANGenS projects have joined hands for the fourth time in June 2024 to implement a training series aiming at improving knowledge associated with next-generation sequencing (NGS) technologies and their applications in the field of tuberculosis.

At the occasion of the ASLM 2023 conference organized in Cape Town on 12-15 December 2023 and under the lead of ASLM the TB-CAPT consortium organized the TB specific side event TB rapid diagnostics: Can we achieve transformation and bridge the access gap?

This year’s EDCTP Forum in Paris offered an excellent opportunity for the TB-CAPT consortium to showcase exciting results from its research activities implemented since the start of the project.

The TB-CAPT, PanACEA and SeqTreat consortia were pleased to hold a third iteration of the popular online training series “Mycobacterium tuberculosis NGS made easy: data analysis step-by-step”, organized from October 2-6, 2023.

From 02 - 04 October the TB-CAPT consortium convened for a face-to-face progress meeting in Dar-es-Salaam, Tanzania, hosted by our local project partners from Ifakara Health Institute.

In expectation of the second UN General Assembly High-level Meeting on the fight against tuberculosis that will be held on 22 September 2023, the Lancet Commission on tuberculosis has just published an update to its last report dating from 2018:

The TB-CAPT, PanACEA and SeqTreat consortia are pleased to announce a second iteration of the popular online training series “Mycobacterium tuberculosis NGS made easy: data analysis step-by-step”, organized from January 9-13, 2023.

Last week, TB-CAPT’s dissemination partner, the African Society for Laboratory Medicine (ASLM), hosted the sixth edition of their annual meeting ASLM Laboratory Systems Strengthening Community of Practice (LabCoP). The recording is now available.

This week, from October 11-14, TB-CAPT Dissemination Lead, African Society for Laboratory Medicine (ASLM), will host the sixth edition of their annual event the ASLM Laboratory Systems Strengthening Community of Practice (LabCoP). TB-CAPT will host a satellite session on the second day of the event, October 12.

The TB-CAPT consortium recently reached two important milestones, as the group successfully enrolled the first patients in both the CORE trial and the HIV trial. In this article, we look closer at these achievements and provide a brief overview of the two trials.

Members of the TB-CAPT consortium have developed a training package on the application of next-generation sequencing (NGS) technologies in the field of tuberculosis (TB). After a successful 4-day training event in March this year, a 1-day follow-up training session was held on July 20.

The TB-CAPT group is entering an exciting period, with recruitment for two trials – the CORE and HIV trials – scheduled to start this summer. In preparation for this, site initiation visits and trainings were recently conducted in Tanzania and Mozambique.

On March 21-24, the TB-CAPT consortium hosted a free-of-charge training in collaboration with the PanACEA and Seq&Treat projects, titled ‘Mycobacterium tuberculosis complex (MTBC) next-generation sequencing (NGS) made easy: data analysis step-by-step.’

With support from TB-CAPT, FIND has developed a training video to support clinical sites with the implementation of the KNCV Tuberculosis Foundation’s SOS stool processing method, a simple method to diagnose TB which uses stool as an alternative type of sample.

The TB-CAPT consortium has successfully completed enrolment for the XDR trial, undertaken by clinical sites in Green Point (Cape Town) and Gqeberha (formerly Port Elizabeth), South Africa. Initial data analysis began late last year, and the interim results for the feasibility aspects of the study look promising.

The TB-CAPT XDR trial, led by Helen Cox and Chad Centner of the University of Cape Town (UCT) in South Africa, will evaluate the use of a new cartridge on GeneXpert, an automated tuberculosis (TB) molecular test. This rapid test can identify resistance to key drugs used in the treatment of drug resistant TB.

Last week, two years after the UN High Level Meeting (UNHLM) on TB, the WHO and partners released a progress report to take stock of progress made in meeting the WHO’s End TB strategy, Sustainable Development Goals, and UNHLM targets for TB.